Clinical trials: Axillary Hidradenitis Suppurativa
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06958211
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 107 sites in United States, Belgium and 7 more
- Volunteers
- 573 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week…
- Trial name
- STOP-HS1 (NCT05620823)
- Testing
- Povorcitinib
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 608 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT02904902
- Testing
- adalimumab
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06956235
- Testing
- Tulisokibart
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 149 people
- Sponsor
- Merck Sharp & Dohme LLC
Hidradenitis Suppurativa
Pathophysiological Basis of Hidradenitis Suppurativa
HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous…
- Trial name
- NCT06370052
- Testing
- excision
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Center Rijeka
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Hidradenitis Suppurativa Patient Experience With Humira Treatment
Hidradenitis suppurativa (HS) is a chronic relapsing condition with significant psychosocial impact and morbidity, but that doesn't mean that patients will necessarily be adherent to recommended treatments.
- Trial name
- NCT04132388
- Testing
- Electronic Reporting, Adalimumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Hidradenitis Suppurativa (HS)
Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
This study assesses Humira's® real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- SOLACE (NCT02896920)
- Where
- 22 sites in Canada
- Volunteers
- 165 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Hidradenitis Suppurativa
Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa
The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study.
- Trial name
- NCT01063270
- Testing
- Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa
: Treatment of chronic, recalcitrant HS presents significant challenges and frustration to both the patient and the provider. In chronic, recalcitrant HS, wide surgical excision is considered the treatment of choice.13 In 2016…
- Trial name
- NCT05255575
- Testing
- Ertapenem
- Where
- United States
- Sponsor
- Henry Ford Health System
Herpes Genitalis, Genital Wart
Safety and Efficacy of Laser Therapy in Gynaecology
The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g.
- Conditions
- Herpes Genitalis, Genital Wart, Lichen Sclerosus, Cervical Intraepithelial Neoplasia
- Trial name
- NCT04073082
- Where
- Slovenia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Juna d.o.o.
Inflammatory Bowel Diseases, Ulcerative Colitis
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid
- Trial name
- MISTIC (NCT04191395)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
- Trial name
- SHARPS (NCT02808975)
- Testing
- Adalimumab
- Where
- 55 sites in United States, Belgium and 21 more
- Volunteers
- 206 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study.
- Trial name
- NCT05997277
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin.
- Trial name
- WMCREI (NCT07155239)
- Testing
- AviClear Lase Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wynn Medical Center
Hidradenitis Suppurativa (HS)
Autophagy Dysfunction in Hidradenitis Suppurativa
The pathogenesis of HS is still poorly understood: the pilosebaceous tropism and the fact that patients respond to combinations of antibiotics and/or immunosuppressive treatments suggest the involvement of 3 factors that would be…
- Trial name
- AUTOPH-HS (NCT05723757)
- Testing
- blood sampling
- Volunteers
- 50 people
- Sponsor
- Association pour la Recherche Clinique et Immunologique